Anthera Pharmaceuticals (NASDAQ:ANTH) : Traders are bullish on Anthera Pharmaceuticals (NASDAQ:ANTH) as it has outperformed the S&P 500 by a wide margin of 10.28% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 18.3%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 19.81% in the last 1 week, and is up 12.06% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The company shares have dropped -53.31% from its 1 Year high price. On Jul 24, 2015, the shares registered one year high at $11.65 and the one year low was seen on Feb 8, 2016. The 50-Day Moving Average price is $3.38 and the 200 Day Moving Average price is recorded at $3.52.
The stock has recorded a 20-day Moving Average of 19.91% and the 50-Day Moving Average is 12.77%.
Anthera Pharmaceuticals (NASDAQ:ANTH): stock turned positive on Friday. Though the stock opened at $3.51, the bulls momentum made the stock top out at $3.94 level for the day. The stock recorded a low of $3.48 and closed the trading day at $3.81, in the green by 12.72%. The total traded volume for the day was 2,187,146. The stock had closed at $3.38 in the previous days trading.
In an insider trading activity,The (Chief Medical Officer) of Anthera Pharmaceuticals Inc, Hislop Colin sold 12,500 shares at $5.31 on November 13, 2015. The Insider selling transaction had a total value worth of $66,375. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Anthera Pharmaceuticals Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases. The Companys primary Phase 3 product candidate blisibimod targets elevated levels of Bcell activating factor (BAFF) which has been associated with a variety of Bcell mediated autoimmune diseases including systemic lupus erythematosus or lupus IgA nephropathy lupus nephritis multiple myeloma and others. The Companys second product candidate Sollpura (liprotamase) is a Phase III investigational pancreatic enzyme replacement therapy (PERT) intended for the treatment of patients with exocrine pancreatic insufficiency (EPI) often seen in patients with cystic fibrosis and other conditions.